ERBB2 and breast carcinoma: There are a couple of pre‐clinical trials examining CAR‐macrophages’ ability to treat solid tumors.[59] For example, phagocytes CAR‐macrophages and HER2 targeting CAR‐macrophages were used to treat liver cancer and breast cancer respectively.[60] Another feature of CAR‐macrophages is that they can respond to the tumor environmental stimuli and transit into a favorable phenotype against immunosuppressive TME.